Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
4/29/2026, 12:00:00 AM
Received two clinical trial approvals from China's NMPA for its self-developed Class 1 innovative drug, HS-10522 tablets, for the treatment of uncontrolled hypertension and primary aldosteronism.
Korean Translation
자체 개발 1등급 혁신 신약 HS-10522 정제에 대해 중국 국가약품감독관리국(NMPA)으로부터 두 건의 임상시험 승인을 획득함. 해당 임상시험은 조절되지 않는 고혈압 및 원발성 알도스테론증 치료를 위한 것임.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
6/30/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Earnings Release
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
5/18/2026, 12:00:00 AM
Celltrion Inc (068270) · Earnings Release
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
5/8/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Other
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
5/1/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
4/30/2026, 12:00:00 AM